Turning Point Brands Stock Rises Amid Positive Market Trends
Turning Point Brands Inc. shares rose by 9.97% as the stock crossed above its 5-day SMA, reflecting a positive shift in market sentiment.
Despite recent FDA approval delays impacting investor confidence, the company's nicotine pouch segment has shown remarkable growth, achieving a 266% year-over-year increase in revenue last quarter. This growth, alongside a strong partnership with FRE Nicotine Pouches, which enhances brand visibility across major sports properties, is expected to drive future sales and market penetration.
The implications of this growth are significant, as Turning Point Brands continues to solidify its position in the premium nicotine market. Investors may view the current price movement as a potential buying opportunity, especially if they believe that the FDA concerns are temporary and that the company's revenue streams remain stable.
Trade with 70% Backtested Accuracy
Analyst Views on TPB
About TPB
About the author

- Stake Reduction Transaction: Crown Advisors Management, Inc. reduced its stake in Turning Point Brands by 35,000 shares in Q1 2026, with an estimated trade value of $3.90 million, reflecting the company's risk management strategy amid market volatility.
- Decline in Holding Value: This reduction resulted in a $4.12 million decline in the value of Turning Point's holdings at quarter-end, highlighting the stock's volatility and uncertainty in the market.
- Sales Growth Highlight: Turning Point Brands saw a 133% year-over-year surge in Modern Oral product sales to $52 million, now accounting for 42% of total company sales, showcasing strong performance in emerging product categories.
- Market Performance Analysis: Although Turning Point's stock has underperformed the S&P 500, it has climbed over 20% in the past year, indicating ongoing investor interest in its growth potential despite regulatory and consumer trend uncertainties.
- Share Reduction Details: Crown Advisors sold 35,000 shares of Turning Point Brands (TPB) in Q1, with an estimated transaction value of $3.90 million, reflecting a risk management strategy amid market volatility.
- Decline in Position Value: The quarter-end position value decreased by $4.12 million, which includes both the impact of the share sale and underlying price fluctuations, indicating the company's cautious approach in an uncertain market environment.
- Sales Performance Analysis: Turning Point Brands saw a 133% year-over-year surge in Modern Oral product sales to $52 million, now accounting for 42% of total sales, demonstrating the company's strong competitive position amid rapidly changing consumer trends.
- Profitability Challenges: Despite total revenue climbing 16.8% to $124.3 million, net income fell 19% to $11.7 million, highlighting the pressures from rising selling and marketing expenses as the company invests in expanding its oral nicotine business.
- Sales Growth: Turning Point Brands reported net sales of $124.3 million for the quarter, reflecting a nearly 17% year-over-year increase that surpassed analyst expectations of $123.8 million, indicating strong performance in the tobacco market and solidifying its market position.
- Profitability Challenges: Despite the sales increase, non-GAAP net income fell by 11% to $14.8 million, or $0.76 per share, highlighting challenges in profitability that could impact investor confidence and market perception.
- Divergent Product Line Performance: The Stoker smokeless tobacco line saw a remarkable 48% sales increase to $87.6 million, driven by heightened demand for modern oral products, while the Zig-Zag rolling papers line experienced a 22% decline to $36.7 million, illustrating the diversity of the product portfolio and shifting market demands.
- Optimistic Future Outlook: Management raised the sales forecast for modern oral products to $210 million to $225 million for 2026, up from the previous estimate of $180 million to $190 million, which is expected to drive adjusted EBITDA to between $70 million and $90 million, reflecting the company's confidence in future growth.
- Profit Decline: Turning Point Brands reported a Q1 net profit of $11.67 million, translating to $0.60 per share, down from $14.40 million and $0.79 per share last year, indicating a weakening in profitability that may affect investor confidence.
- Revenue Growth: Despite the profit decline, the company achieved a 16.8% year-over-year revenue increase to $124.28 million from $106.44 million last year, suggesting a robust demand for its products in the market.
- Market Performance: The revenue growth is attributed to improved market acceptance of the company's offerings, and while profitability has declined, the increase in revenue may provide necessary funding for future business expansion and investments.
- Future Outlook: The company needs to focus on restoring profitability to address market competition and cost pressures, ensuring continued revenue growth and enhancement of shareholder value.
- Earnings Announcement: Turning Point Brands is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimate at $0.73, reflecting a 19.8% year-over-year decline, while revenue is projected at $115.67 million, indicating an 8.7% year-over-year increase.
- Historical Performance: Over the past two years, TPB has surpassed EPS and revenue estimates 88% of the time, demonstrating the company's financial stability and market confidence.
- Expectation Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with two downward adjustments, and similarly, revenue estimates have seen no upward revisions but three downward adjustments, indicating a cautious market outlook on the company's future performance.
- Market Dynamics: Despite setbacks in the FDA PMTA fast-tracking process, Turning Point Brands has outlined a sales target of $220 million to $240 million for modern oral products, highlighting the company's growth potential and strategic focus in the white pouch market.
- Quarterly Dividend Announcement: Turning Point Brands declares a quarterly dividend of $0.08 per share, consistent with previous distributions, demonstrating the company's ongoing ability to maintain stable cash flow despite market challenges.
- Dividend Yield: The forward yield of 0.39% reflects the company's capacity to provide returns to shareholders in the current economic environment, thereby enhancing investor confidence.
- Payment Schedule: The dividend is payable on July 10, with a record date of June 19 and an ex-dividend date also on June 19, ensuring shareholders receive timely returns and promoting long-term holding intentions.
- Sales Target Outlook: Turning Point Brands outlines a sales target of $220 million to $240 million for modern oral products, indicating a proactive strategy in expanding its market presence as white pouch sales accelerate.










